DNA Valuation

Ginkgo Bioworks Holdings Inc

Add to Watchlist

Advanced Chart

12.670

+0.5(4.108%)1D

Overview
Forecast
Valuation
Earnings

DNA Relative Valuation

DNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DNA is overvalued; if below, it's undervalued.

Historical Valuation

Ginkgo Bioworks Holdings Inc (DNA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.92 is considered Overvalued compared with the five-year average of -16.07. The fair price of Ginkgo Bioworks Holdings Inc (DNA) is between 6.15 to 9.92 according to relative valuation methord. Compared to the current price of 12.17 USD , Ginkgo Bioworks Holdings Inc is Overvalued By 22.62%.

Relative Value

Fair Zone

6.15-9.92

Current Price：12.17

22.62%

Overvalued

-2.60

Trailing

Forward

-6.41

EV/EBITDA

Ginkgo Bioworks Holdings Inc. (DNA) has a current EV/EBITDA of -6.41. The 5-year average EV/EBITDA is -18.77. The thresholds are as follows: Strongly Undervalued below -89.89, Undervalued between -89.89 and -54.33, Fairly Valued between 16.79 and -54.33, Overvalued between 16.79 and 52.35, and Strongly Overvalued above 52.35. The current Forward EV/EBITDA of -6.41 falls within the Historic Trend Line -Fairly Valued range.

-2.47

EV/EBIT

Ginkgo Bioworks Holdings Inc. (DNA) has a current EV/EBIT of -2.47. The 5-year average EV/EBIT is -9.94. The thresholds are as follows: Strongly Undervalued below -66.18, Undervalued between -66.18 and -38.06, Fairly Valued between 18.18 and -38.06, Overvalued between 18.18 and 46.30, and Strongly Overvalued above 46.30. The current Forward EV/EBIT of -2.47 falls within the Historic Trend Line -Fairly Valued range.

3.86

Ginkgo Bioworks Holdings Inc. (DNA) has a current PS of 3.86. The 5-year average PS is 13.39. The thresholds are as follows: Strongly Undervalued below -16.24, Undervalued between -16.24 and -1.43, Fairly Valued between 28.20 and -1.43, Overvalued between 28.20 and 43.02, and Strongly Overvalued above 43.02. The current Forward PS of 3.86 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Ginkgo Bioworks Holdings Inc. (DNA) has a current P/OCF of 0.00. The 5-year average P/OCF is -17.10. The thresholds are as follows: Strongly Undervalued below -74.59, Undervalued between -74.59 and -45.84, Fairly Valued between 11.65 and -45.84, Overvalued between 11.65 and 40.40, and Strongly Overvalued above 40.40. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Ginkgo Bioworks Holdings Inc. (DNA) has a current P/FCF of 0.00. The 5-year average P/FCF is -14.28. The thresholds are as follows: Strongly Undervalued below -60.50, Undervalued between -60.50 and -37.39, Fairly Valued between 8.83 and -37.39, Overvalued between 8.83 and 31.94, and Strongly Overvalued above 31.94. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Ginkgo Bioworks Holdings Inc (DNA) has a current Price-to-Book (P/B) ratio of 1.10. Compared to its 3-year average P/B ratio of 1.66 , the current P/B ratio is approximately -33.74% higher. Relative to its 5-year average P/B ratio of 3.34, the current P/B ratio is about -67.06% higher. Ginkgo Bioworks Holdings Inc (DNA) has a Forward Free Cash Flow (FCF) yield of approximately -40.05%. Compared to its 3-year average FCF yield of -35.31%, the current FCF yield is approximately 13.45% lower. Relative to its 5-year average FCF yield of -26.14% , the current FCF yield is about 53.25% lower.

1.08

P/B

Median3y

1.66

Median5y

3.34

-40.65

FCF Yield

Median3y

-35.31

Median5y

-26.14

Competitors Valuation Multiple

The average P/S ratio for DNA's competitors is 0.97, providing a benchmark for relative valuation. Ginkgo Bioworks Holdings Inc Corp (DNA) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -11.75%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DNA.N

Ginkgo Bioworks Holdings Inc

Performance Decomposition

Market capitalization of DNA increased by 81.91% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.82 to -2.16.

The secondary factor is the Revenue Growth, contributed -11.75%to the performance.

Overall, the performance of DNA in the past 1 year is driven by P/E Change. Which is more unsustainable.

-11.75%

56.21M → 49.60M

Revenue Growth

-68.54%

-386.40 → -121.56

Margin Expansion

162.20%

-0.82 → -2.16

P/E Change

81.91%